📰 Analytical Reference Standards News
Page 2 - Analytical Reference Standards News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Analytical Reference Standards. Real-time updates on events, politics, business and more.
January 1, 2024
StockNews.com upgraded shares of ChromaDex (NASDAQ:CDXC – Free Report) from a buy rating to a strong-buy rating in a report released on Friday. ChromaDex Stock Down 3.4 % NASDAQ CDXC opened at $1.43 on Friday. The company has a market capitalization of $107.42 million, a price-to-earnings ratio of -15.89 and a beta of 1.72. ChromaDex […]
January 1, 2024
StockNews.com upgraded shares of ChromaDex (NASDAQ:CDXC – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Friday morning. ChromaDex Trading Down 3.4 % CDXC stock opened at $1.43 on Friday. The business’s 50-day moving average price is $1.41 and its two-hundred day moving average price is […]
December 31, 2023
ChromaDex (NASDAQ:CDXC – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Friday. ChromaDex Stock Performance Shares of ChromaDex stock opened at $1.43 on Friday. The firm has a fifty day moving average of $1.41 and a two-hundred day […]
December 24, 2023
StockNews.com upgraded shares of ChromaDex (NASDAQ:CDXC – Free Report) from a buy rating to a strong-buy rating in a research report report published on Wednesday. ChromaDex Stock Performance CDXC stock opened at $1.45 on Wednesday. The stock has a market capitalization of $108.93 million, a price-to-earnings ratio of -16.11 and a beta of 1.72. ChromaDex […]
December 8, 2023
StockNews.com upgraded shares of ChromaDex (NASDAQ:CDXC – Free Report) from a buy rating to a strong-buy rating in a research report report published on Monday. Separately, HC Wainwright reiterated a buy rating and issued a $5.00 price objective on shares of ChromaDex in a research note on Thursday, August 10th. Check Out Our Latest Research […]
November 14, 2023
ChromaDex (NASDAQ:CDXC – Get Free Report) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Monday. Separately, HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of ChromaDex in a research report on Thursday, August 10th. View Our Latest […]
August 13, 2023
HC Wainwright reaffirmed their buy rating on shares of ChromaDex (NASDAQ:CDXC – Free Report) in a research note published on Thursday morning, Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright also issued estimates for ChromaDex’s Q4 2024 earnings at $0.03 EPS. Other analysts have also recently issued research reports […]
July 3, 2023
StockNews.com upgraded shares of ChromaDex (NASDAQ:CDXC – Free Report) from a buy rating to a strong-buy rating in a report issued on Friday. Other equities research analysts also recently issued research reports about the company. HC Wainwright decreased their target price on ChromaDex from $5.50 to $5.00 and set a buy rating for the company […]
June 21, 2022
ChromaDex Co. (NASDAQ:CDXC – Get Rating) major shareholder Hoi Shuen Solina Holly Chau acquired 60,037 shares of the stock in a transaction dated Thursday, June 16th. The stock was acquired at an average price of $1.66 per share, for a total transaction of $99,661.42. Following the purchase, the insider now directly owns 6,925,641 shares in […]
June 20, 2022
IM Cannabis (NASDAQ:IMCC – Get Rating) and ChromaDex (NASDAQ:CDXC – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends. Earnings and Valuation This table compares IM Cannabis and ChromaDex’s […]